BioDelivery Sciences International, Inc., reported higher than expected third quarter results, leading the company to raise its 2019 net sales views, the company announced in a press release today.

“The success achieved in the third quarter marks the sixth straight quarter of sustained rapid growth and fuels our confidence to raise total net sales expectations for full year 2019 and provide expectations for 2020,” said CEO Herm Cukier. “Given the increased utilization by physicians, significantly expanded access across payers, and tailwinds from federal health policy initiatives, I believe BELBUCA and Symproic are positioned for sustained growth.”

BioDelivery’s net revenue increased 114 percent to an all-time high of $30.3 million, exceeding analysts’ estimates of $28.27 million. The company said the growth was driven by sales in BELBUCA and Symproic prescriptions.

BELBUCA net sales increased 115 percent to $26.5 million, compared to the same quarter 2018. Symproic net sales for the third quarter decreased by $1.0 million from the second quarter due to commercialization following an acquisition of the product.

BioDelivery raised full year 2019 expectations for total net sales to $105 million to $110 million compared to $101 million to $105 million as previously anticipated. The company provided net sales expectations for the full year 2020 to be $165 million to $175 million.

BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. Shares of BioDelivery closed at $5.85 on Tuesday, up 1 cent.